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The recently developed science of gene transferholds great promise for interventions in cardio-
vascular disease. Under the theory that cytokines
and protein products of recombinant genes intro-
duced into a transplanted heart may contribute to
beneficial alterations in alloreactivity, such as reduc-
tions in allograft coronary artery disease and acute
rejection, gene transfer into the adult heart is being
investigated. If, for instance, one could introduce
gene coding for cytokines known to modulate the
host immune response, the transplanted organ may
enjoy better survival.1 Furthermore, such ap-
proaches may allow the avoidance or greatly re-
duced dosing of conventional systemic immunosup-
pression.
Gene transfer into the adult heart has been
achieved in vivo by direct myocardial injection2 and
by intracoronary infusion.3 To increase the efficacy
of gene transfer and the uptake of recombinant
deoxyribonucleic acid by target cells, two vehicles
for gene transfer have been successfully used. These
vehicles are (1) cationic liposomes and (2) viral
vectors.4 Some studies have used these vehicles in
combination. In the adult heart, with nondividing
cardiac cells, recombinant adenoviral vectors have
emerged as the most feasible vehicle for introduc-
tion of genes.5 Previous studies have focused largely
on so-called “reporter” genes for demonstration of
transgene expression in the study of various transfer
strategies.
Brauner and associates,1 in the December 1997
issue of the Journal, sought to evaluate the utility of
intraccoronary gene transfer for therapeutic benefit
in cardiac transplantation in vivo. They constructed
recombinant adenoviral vectors including each of
two immunosuppressive cytokines, viral interleu-
kin-10 (vIL-10) and human transforming growth
factor-b1 (TGF-b1). Both these agents have immu-
nosuppressive properties and both have been shown
to inhibit host responses in allograft models. IL-10
potently inhibits production of IL-2, TNF-a, and
TNF-b, and interferon-g.6 These effects have a
pronounced impact on antigen presentation in the
allograft setting. TGF-b1 down-regulates both cellu-
lar and humoral pathways. At physiologic levels, it
suppresses production of IL-2, IL-6, and TNF by
alloantigen-specific T lymphocytes. Furthermore, B
cell proliferation and immunoglobulin production
are reduced by this agent.7
The authors have previously tested the abilities of
these adenoviral vectors to effect expression of
cytokine genes in cardiac allografts. Their studies
have led to the development of a model for efficient
ex vivo intracoronary transfer of the genes during
cold preservation. In the current study, after the
slow intracoronary vector delivery method, the au-
thors studied the resulting myocardial distribution
and magnitude of expression in the heart via a
reporter gene, Escherichia coli b-galactosidase.
Transcription of the cytokine genes was docu-
mented by polymerase chain reaction. The func-
tional effects of the incorporation of these immuno-
suppressive genes was then examined in an attempt
to prolong allograft survival in vivo.
The authors demonstrated consistent high uptake
of the vectors by the grafts, averaging 81% for all
vectors. Furthermore, the cytokine deoxyribonucleic
acid sequences could be detected by polymerase
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chain reaction in the grafts, confirming successful
gene transfer and expression in myocardial cells.
There was some difficulty with distribution of the
reporter gene and, by analogy, of the cytokine
transgenes. Subepicardial regions took up much
more of the genes than the mid-wall and subendo-
cardial regions with the slow intracoronary introduc-
tion. The authors modified the administration by
intermittent external compression of the left ventri-
cle during the slow inflow of vectors, simulating
higher pulsatile pressure. When this method was
used, there was more even distribution of the re-
porter gene, although still with a predilection for the
subepicardial regions.
In the attempt to determine the functional impli-
cations of these incorporated transgenes, allograft
survival was investigated in animals receiving the
vector only (controls) and in animals receiving the
vector with attached cytokines. Heterotopic allo-
grafts transfected with the vector alone (controls)
maintained mechanical activity for 6.9 6 0.9 days
after transplantation. Mean survival, on the other
hand, for the TGF-b–infected grafts was 11.1 6 1.7
days (p , 0.0004 compared with controls). Similarly,
IL-10–infected allografts survived for 11.2 6 3 days
(p , 0.0004 compared with controls). Furthermore,
average rejection scores for the cytokine-infected
grafts were significantly lower than for controls (p ,
0.001).
This and other studies have demonstrated the
feasibility of myocardial gene transfer by intracoro-
nary administration. Replication-defective adenovi-
ral vectors are apparently the most efficient vehicle
for in vivo gene transfer in nondividing cells such as
myocytes, demonstrating several-fold greater trans-
duction than liposomal compounds. The use of viral
vectors in vivo raises some safety concerns. How-
ever, the type 5 adenoviruses used as vectors have
not been associated with any known malignant
diseases. Furthermore, this entity has been used for
routine vaccination in human beings with no appar-
ent ill-effects. There are two problems limiting the
potential usefulness of adenoviral vectors for gene
delivery, specifically with respect to transplant ap-
plications. First, the newly introduced gene remains
episomal and is not incorporated in the permanent
genetic makeup of the cell. This results in transient
expression of the gene product and short-lived du-
ration of the immunosuppressive effects. The second
problem relates to the use of transgenes in the
transplant setting relates to initial cellular immune
activation and antigen-presenting cell function.
These processes occur immediately after the estab-
lishment of reperfusion and therefore are outside
the time frame of transgene expression. Rather, they
occur during the initial transcription and translation
of the inserted genes. It will thus be necessary to
supplement gene therapy with either conventional
immunosuppression or soluble cytokines until the
transgene expression of cytokines can occur.
The present study presents a first report of a
functioning gene therapy strategy in the setting of
heart transplantation targeted to modulation of the
allograft response. Acute allograft rejection is
shown to be significantly inhibited by the introduc-
tion of exogenous immunosuppressive cytokine
genes delivered by ex vivo intracoronary gene trans-
fer. Viral IL-10 and human TGF-b1 genes, attached
to adenovirus vectors, were able to be introduced
during cold preservation of the heart and resulted in
internalization, transcription, and expression of both
cytokines within the graft. Allograft survival was
prolonged significantly, a result that is intriguing and
suggests that future approaches may be applicable
to clinical transplantation. Many steps remain be-
fore human application can be entertained. How-
ever, other authors are investigating systems of gene
transfer in settings related to thoracic surgery.
Takeda and associates8 have used a liposome-medi-
ated method to introduce the endothelin-1 gene into
rodents and have demonstrated the development of
a lesion very similar to bronchiolitis obliterans in
these animals. This represents an advance in our
understanding of this disease process. Work in our
own laboratory by Al-Dossari and coworkers9 pro-
duced the first large-animal model of bronchiolitis
obliterans. The use of gene transfer strategies prom-
ises to further elucidate the mechanisms of this
disease and, very likely, many other diseases.
Boasquevisque and colleagues10 have demonstrated
gene transfer into lung allografts using adenoviral
vectors. There are many attempts ongoing to ex-
plore gene transfer strategies in transplantation,
neoangiogenesis, and enhancement of myocardial
contractility. The current problems preventing effec-
tive application of these therapies to human disease
have already been alluded to. Gene transfer is a
short-lived therapy, as currently described. There
may very likely be immune responses in the host to
the vectors that are introduced, further limiting the
potential of this strategy. The viruses used as vectors
need to be demonstrably safe for use in human
beings. Despite these and other concerns, gene
transfer holds tremendous promise both as a tool to
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investigate disease mechanisms and as a potential
novel and very specifically targeted therapy. An-
other realm of potential utility for gene transfer
approaches is the field of xenograft transplantation.
In attempts to make pig organs more acceptable to
human beings, some investigators have bred trans-
genic pigs to express human complement inhibitors
on their endothelial surfaces. This prevents the
activation of complement by immunoglobulin M
natural antibodies and thereby abrogates hyper-
acute rejection.11 The creation of transgenic animals
is time and labor intensive and very expensive. Gene
transfer strategies would potentially possess a great
appeal for modulation of the xenograft response.
The local introduction of complement inhibitors and
cytokines could significantly improve xenograft or-
gan survival and help approach the ideal of organ
tolerance with reduced requirement for systemic
immunosuppression.
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